Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT

Arcutis Biotherapeutics — Q2 2023 Earnings Presentation

17 slides from Arcutis Biotherapeutics's earnings presentation, Aug 8, 2023

  1. Slide 1: 2nd Quarter 2023 Financial Results & Business Update

    2nd Quarter 2023 Financial Results & Business Update August 8, 2023

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers This presentation and the accompanying oral presentation candidates, and our ability to serve those markets; our to time, whether as a result of new information, future contain “forward-looking” statements that are based on our commercialization, marketing and manufacturing capabil

  3. Slide 3: Today's Speakers

    Today’s Speakers Frank Watanabe Ayisha Jeter President & CEO Chief Commercial Officer (interim) Patrick Burnett, MD, PhD, FAAD Scott Burrows Chief Medical Officer Chief Financial Officer ©Copyright 2023. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 3

  4. Slide 4: Speakers & Agenda: Business Review

    Speakers & Agenda Business Review ©Copyright 2023. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 4

  5. Slide 5: Q2 Business Update – Near-Term Execution Creating Foundation for Long-Term Growth

    Q2 Business Update – Near-Term Execution Creating Foundation for Long-Term Growth ZORYVE® (roflumilast) cream 0.3% launch in psoriasis strengthening ~40% prescription growth in Q2 compared to Q1 >130 million U.S. commercial lives covered, including all three large PBMs GTN improvement in Q2; executi

  6. Slide 6: Topical Roflumilast: A Transformational 4-in-1 Asset Targeting 13 Million Patient Market

    Topical Roflumilast: A Transformational 4-in-1 Asset Targeting 13 Million Patient Market Topically Treated U.S. Patient Opportunity: PsO PsO + Seb Derm PsO + Seb Derm + AD PsO + Seb Derm + AD (2 MM) (>4 MM) (>6.5 MM) [Derm Offices + Outside Derm] (~13 MM) Potential Launch Timing: 1Q 2024 2H 2024 1H

  7. Slide 7: Speakers & Agenda: Commercial Update

    Speakers & Agenda Commercial Update ©Copyright 2023. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 7

  8. Slide 8: ZORYVE PsO Launch Continues to Strengthen

    ZORYVE PsO Launch Continues to Strengthen ~ 40% TRx growth Q2 vs. Q1, with Growth Continuing in Q3 3,000 2,500 2,000 WEEKLY TRX 1,500 1,000 Q2 2023 TRx 500 0 4-Nov 17-Feb 19-Aug 2-Sep 30-Sep 2-Dec 5-May 30-Dec 24-Mar 16-Sep 23-Sep 28-Oct 16-Dec 23-Dec 20-Jan 3-Mar 24-Feb 26-May 21-Apr 12-May 9-Jun 1

  9. Slide 9: ~80% Commercial Coverage <12 Months into Launch; >90% Lives Covered Without PA

    ~80% Commercial Coverage <12 Months into Launch; >90% Lives Covered Without PA > 130 > 90% Covered Million Without Covered Commercial PA Lives Total US Commercial Market = 165 million lives Covered Commercial Lives = >130 million Positive Halo Building on Prescriber Confidence with Coverage PA = pri

  10. Slide 10: ZORYVE Clinical Profile + Pricing & Access Strategy Resonating with Payers

    ZORYVE Clinical Profile + Pricing & Access Strategy Resonating with Payers Express Scripts PBM #2 CVS Caremark ➢ Effective Nov. ‘22 ➢ Effective May ‘23 ➢ Effective July ‘23 ➢ No Prior ➢ No Prior ➢ No Prior Authorization Authorization Authorization ➢ Tier 3 ➢ Tier 2 ➢ Tier 2 ➢ 2 Step Edits (TCS + ➢ S

  11. Slide 11: Progress Towards Sustained ZORYVE Growth

    Progress Towards Sustained ZORYVE Growth Commercial Success Drive Prescriber Patient Engagement Broad, High- Awareness and Use and Positive Experience Quality Access • >7,500 unique • Refills building nicely, • >130 million writers since contributing 1/3rd of commercial lives launch TRx in July cove

  12. Slide 12: Speakers & Agenda: R&D Update

    Speakers & Agenda R&D Update ©Copyright 2023. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 12

  13. Slide 13: Key Upcoming Regulatory Milestones Remain on Track

    Key Upcoming Regulatory Milestones Remain on Track Key Accomplishments / Milestones Indication Timing 1st Subject Enrolled in AA Cohort Alopecia Areata INTEGUMENT-PED Topline Data Atopic Dermatitis Q3 2023 Submit sNDA for Roflumilast Cream in Ages 6+ Atopic Dermatitis Late Q3/Early Q4 2023 Potential

  14. Slide 14: Speakers & Agenda: Financial Results

    Speakers & Agenda Financial Results ©Copyright 2023. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 14

  15. Slide 15: Q2 2023 Financial Results

    Q2 2023 Financial Results GAAP Reported $ Millions, Except Net Loss Per Share Q2 2023 Q2 2022 YoY Change Product Revenues, Net $4.8 - 4.8 Other Revenues 0.4 - 0.4 Total Revenues 5.2 - 5.2 Cost of Sales 0.8 - 0.8 R&D Expense 25.2 38.2 (13.0) SG&A Expense 46.0 27.6 18.3 Total Operating Expense 72.0 65

  16. Slide 16: Well Capitalized with ~$270 Million of Cash

    Well Capitalized with ~$270 Million of Cash $ Millions, except average shares GAAP Reported Cash Flow & Balance Sheet Data Q2 2023 Cash, Cash Equivalents, and Marketable securities (June 30, 2023) $269.6 Net cash used in operating activities 66.5 Long-term debt, net (June 30, 2023) 199.8 Weighted av

  17. Slide 17: Thank You Q&A

    Thank You Q&A ©Copyright 2023. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. 17

Arcutis Biotherapeutics — Q2 2023 Earnings Presentation on 6ix